AG
BIO icon

Ascent Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ascent Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-810
Closed -$456K – 458
2022
Q2 		$456K Sell
810
-436
-35% -$227K 0.05% 313
2022
Q1 		$702K Sell
1,246
-38
-3% -$22.9K 0.08% 261
2021
Q4 		$752K Buy
+1,284
New +$961K 0.1% 240

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ascent Group's BIO Position: Q3 2022 in Review

Ascent Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 810 shares — an estimated $456K sold.

Ascent Group first reported a position in BIO in Q4 2021 and held it in 3 quarters. The position peaked at $752K in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Ascent Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Ascent Group sold 810 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $456K.
  • Ascent Group first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 3 quarters.
  • Ascent Group's Bio-Rad Laboratories Class A position peaked at $752K in Q4 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Ascent Group's 13F filing for Q3 2022, filed 15 Nov 2022.